Cervical Cancer Prevention: HPV Vaccine Significantly Reduces Mortality Risk

A recent UK study has revealed that adolescent girls vaccinated against HPV at ages 12-13 have virtually zero mortality from cervical cancer by age 30. This research offers significant hope globally, especially for countries where cervical cancer remains a major threat to women's health. England recorded no deaths from cervical cancer among women aged 20-24 between 2020 and 2024, a historic first. The primary cause of cervical cancer is infection with certain high-risk strains of the Human Papillomavirus (HPV), responsible for 99.7% of cases. Safe and effective HPV vaccines are now widely available and recommended by experts for girls aged 9-14, ideally before the onset of sexual activity, to substantially lower future cancer risk. Beyond cervical cancer, the vaccine also protects against cancers of the neck, throat, mouth, and genital warts. Bangladesh has initiated a national HPV vaccination program for adolescent girls. The World Health Organization (WHO) estimates that if 90% of girls worldwide are vaccinated before age 15, alongside screening, cervical cancer could be eradicated within the next century. A key benefit of vaccination before age 15 is that a single dose is sufficient, reducing costs and ensuring protection before most girls become sexually active. Despite potential parental hesitancy due to misconceptions, the HPV vaccine has minimal side effects, typically limited to mild pain, redness at the injection site, or slight fever. Severe allergic reactions are rare and require prior disclosure. Public health officials urge parents to vaccinate their daughters and encourage others to do the same.